ASCO 2015 Highlights

Abemaciclib (LY2835219): a Dual Inhibitor of CDK4 and CDK6

Mechanism of Action Magnifier – 2016 Desk Reference

Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2

Mechanism of Action Magnifier – 2016 Desk Reference

Ruxolitinib: a Kinase Inhibitor That Inhibits Overactive JAK Pathway Signaling

Mechanism of Action Magnifier – 2016 Desk Reference

Panobinostat: a Histone Deacetylase Inhibitor

Mechanism of Action Magnifier – 2016 Desk Reference

Idelalisib: a Selective Inhibitor of the Delta Isoform of Phosphatidylinositol 3-Kinase

Mechanism of Action Magnifier – 2016 Desk Reference

Ibrutinib: an Inhibitor of Bruton’s Tyrosine Kinase

Mechanism of Action Magnifier – 2016 Desk Reference

Duvelisib (IPI-145): a Dual Inhibitor of Phosphoinositide 3-Kinase (PI3K)-Delta and -Gamma

Mechanism of Action Magnifier – 2016 Desk Reference

Blinatumomab: a Bispecific CD19-Directed CD3 T-Cell Engager

Mechanism of Action Magnifier – 2016 Desk Reference

Dabrafenib plus Trametinib: Two Kinase Inhibitors Used in Combination to Target Different Parts of the MAPK Pathway

Mechanism of Action Magnifier – 2016 Desk Reference

Magnifying Mechanisms of Action: an Exclusive Series to PMO

By Al B. Benson III, MD

Mechanism of Action Magnifier – 2016 Desk Reference

Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.

Page 158 of 330